AddBIO: First patient included in clinical study with Skruvcoat
Publicerad: 2011-05-19
AddBIO AB, reports that the first patient has been included in the
clinical study in which AddBIO's product Skruvcoat is used on
patients undergoing surgery for knee degeneration. The purpose of
the study, which is conducted at the hospital in Hässleholm,
Sweden, is to investigate if implants treated with Skruvcoat have
better fixation in the shinbone and knee joint than implants
without the Skruvcoat coating.
"Screw loosening and infections are serious problems,
particularly in weak bone. Skruvcoat offers a promising solution
through strengthening the bone itself, and we are therefore looking
forward to the results of this study which we hope will result in
fewer complications and less suffering for the patient", says Trine
Vikinge, CEO of AddBIO AB.
Skruvcoat is an implant coating that contains bisphosphonate, a
drug currently used to treat osteoporosis. When the implant is
placed in the bone, the drug is released, strengthening the bone
around the implant and thus reducing the risk of complications.
Skruvcoat is AddBIO's first product from the FibMat
drug-delivery
platform.
The study, which is expected to be completed during 2011, will
include 20 patients undergoing surgical knee joint distraction,
i.e. an alteration of the angle of the knee joint with the purpose
of changing the point of impact. Fixation will be measured after
three months. The study is conducted in association with the
hospital in Hässleholm without specific compensation given to the
hospital.
For additional information, please contact:
Andreas Bunge, CEO Accelerator Nordic AB
+46 70 824 25 25
